Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew W Roberts

Showing results (111-120 of 198) with videos related to

Pageof 20
Sort By:
Blood|February 23, 2013
Low adhesion receptor levels on circulating platelets in patients with lymphoproliferative diseases before receiving Navitoclax (ABT-263)Jianlin Qiao, Simone M Schoenwaelder, Kylie D Mason, et al.
British Journal of Haematology|May 7, 2015
Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignanciesAndrew W Roberts, Ranjana H Advani, Brad S Kahl, et al.
The Journal of Clinical Investigation|May 20, 2006
SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritisPeter K K Wong, Paul J Egan, Ben A Croker, et al.
Blood|March 13, 2015
Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosisRami S Komrokji, John F Seymour, Andrew W Roberts, et al.
Blood|July 29, 2016
Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1Jia-Nan Gong, Tiffany Khong, David Segal, et al.
Hemasphere|November 29, 2023
Relationship Between Venetoclax Exposure and Undetectable Minimal Residual Disease Rates in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of Six Clinical StudiesSathej Gopalakrishnan, Rajeev Menon, Ahmed A Suleiman, et al.
British Journal of Haematology|June 25, 2019
Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphomaPiers Blombery, Richard W Birkinshaw, Tamia Nguyen, et al.
Health Affairs (Project Hope)|April 4, 2022
Many Medicare Beneficiaries Do Not Fill High-Price Specialty Drug PrescriptionsStacie B Dusetzina, Haiden A Huskamp, Russell L Rothman, et al.
Blood|May 9, 2009
Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034)H Miles Prince, Dirk Hönemann, Andrew Spencer, et al.
Blood Advances|January 18, 2025
Final analysis of the phase 1b Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT)Chong Chyn Chua, Sun Loo, Chun Yew Fong, et al.
Pageof 20

Showing results (111-120 of 198) with videos related to

Sort By:
Pageof 20
Blood|February 23, 2013
Low adhesion receptor levels on circulating platelets in patients with lymphoproliferative diseases before receiving Navitoclax (ABT-263)Jianlin Qiao, Simone M Schoenwaelder, Kylie D Mason, et al.
British Journal of Haematology|May 7, 2015
Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignanciesAndrew W Roberts, Ranjana H Advani, Brad S Kahl, et al.
The Journal of Clinical Investigation|May 20, 2006
SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritisPeter K K Wong, Paul J Egan, Ben A Croker, et al.
Blood|March 13, 2015
Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosisRami S Komrokji, John F Seymour, Andrew W Roberts, et al.
Blood|July 29, 2016
Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1Jia-Nan Gong, Tiffany Khong, David Segal, et al.
Hemasphere|November 29, 2023
Relationship Between Venetoclax Exposure and Undetectable Minimal Residual Disease Rates in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of Six Clinical StudiesSathej Gopalakrishnan, Rajeev Menon, Ahmed A Suleiman, et al.
British Journal of Haematology|June 25, 2019
Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphomaPiers Blombery, Richard W Birkinshaw, Tamia Nguyen, et al.
Health Affairs (Project Hope)|April 4, 2022
Many Medicare Beneficiaries Do Not Fill High-Price Specialty Drug PrescriptionsStacie B Dusetzina, Haiden A Huskamp, Russell L Rothman, et al.
Blood|May 9, 2009
Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034)H Miles Prince, Dirk Hönemann, Andrew Spencer, et al.
Blood Advances|January 18, 2025
Final analysis of the phase 1b Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT)Chong Chyn Chua, Sun Loo, Chun Yew Fong, et al.
Pageof 20